MORICIZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H25N3O4S
Molecular Weight	427.517
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)NC1=CC=C2SC3=CC=CC=C3N(C(=O)CCN4CCOCC4)C2=C1

InChI

InChIKey=FUBVWMNBEHXPSU-UHFFFAOYSA-N

InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)

HIDE SMILES / InChI

Molecular Formula	C22H25N3O4S
Molecular Weight	427.517
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1377359 | https://www.drugbank.ca/drugs/DB00680 | https://www.drugs.com/cons/moricizine.html | https://www.ncbi.nlm.nih.gov/pubmed/3310584

Moricizine is an antiarrhythmic agent previously marketed as Ethmozine. It was used for prophylaxis and treatment of serious and life-threatening ventricular arrhythmias. In 2007 it was withdrawn and discontinued for commercial reasons. Moricizine can be administered intravenously but was more commonly provided as an oral formulation.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
voltage-gated calcium channel activity 3 Target ID: GO:0005245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8385537	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ventricular arrhythmia 50 Sources: https://clinicaltrials.gov/ct2/show/NCT00000526	Primary		Approved 8583	ETHMOZINE Approved Use Moricizine is used to correct irregular or rapid heartbeats to a normal rhythm. It is typically prescribed at a dose range of 600 - 900 mg/day, taken as 3 doses every 8 hours. Launch Date 1990

C_max

Value	Dose	Analyte	Population
0.3035 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	150 mg 3 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.444 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.5 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	250 mg 3 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.597 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
0.569 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	150 mg 3 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.747 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.008 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	250 mg 3 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.993 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.5 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	150 mg 3 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	250 mg 3 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2407090	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MORICIZINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	Disc. AE: Electrocardiogram change, Congestive heart failure... AEs leading to discontinuation/dose reduction: Electrocardiogram change (17 patients) Congestive heart failure (11 patient) Atrial fibrillation (4 patients) Nausea (34 patients) Gastrointestinal upset (3 patients) Anxiety (3 patients) Hypoesthesia (2 patients) Tremor of hands (2 patients) Dyspnea (2 patients) Urinary retention (4 patients) Laboratory test abnormality (5 patients) Drug fever (3 patients) Blurred vision (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/

AEs

AE	Significance	Dose	Population
Congestive heart failure	11 patient Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Electrocardiogram change	17 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Dyspnea	2 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Hypoesthesia	2 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Tremor of hands	2 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Anxiety	3 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Blurred vision	3 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Drug fever	3 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Gastrointestinal upset	3 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Nausea	34 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Atrial fibrillation	4 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Urinary retention	4 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/
Laboratory test abnormality	5 patients Disc. AE	900 mg 1 times / day steady, oral Recommended Dose: 900 mg, 1 times / day Route: oral Route: steady Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2407091/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 132 CYP1A2 2153 CYP2B 16 CYP2C 20 CYP2D 3 CYP2E1 1060 CYP3A 227		CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/	no
CYP1A1 272	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/ Page:	yes [IC50 0.43 uM]	2
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/	yes [IC50 0.98 uM]
CYP2B 41	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/	yes [IC50 22.9 uM]
CYP2C 37	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/	yes [IC50 4.7 uM]
CYP2D 4	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/	yes [IC50 80 uM]
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/23121279/	yes
CYP3A 317	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12393941/	yes
CYP3A4 2633	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/23121279/	yes
PXR 51	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/23121279/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6997	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6997
ChemicalBook	CB4493310	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4493310
eMolecules	969296	https://www.emolecules.com/cgi-bin/more?vid=969296
MolPort	MolPort-001-727-947	https://www.molport.com/shop/molecule-link/MolPort-001-727-947
ZINC	ZINC000019340795	http://zinc15.docking.org/substances/ZINC000019340795

PubMed

Title	Date	PubMed
Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.	2010-03-01	20448812
Bayes' Theorem to estimate population prevalence from Alcohol Use Disorders Identification Test (AUDIT) scores.	2009-07	19438421
[The role of reflexotherapy and physical training in the combined treatment and the prevention of paroxysmal form of idiopathic atrial fibrillation].	2009-01-30	19175054
[Immunochemical properties of conjugated antigens from N-substituted phenothiazines and dibenzazepines with antiarrhythmic activity].	2008-10-01	18822782
Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction.	2008-06	18332078
Effect of drugs on defibrillation capacity.	2008	18370441
Steroids in late ARDS?	2007	17666114
Rate-control or rhythm-control: where do we stand?	2005-10-01	16943879
Chiropractic as spine care: a model for the profession.	2005-07-06	16000175
Non-linear heart rate variability and risk stratification in cardiovascular disease.	2005-07-01	16943869
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
[Effect of etmosin on biliary motility disorders in patients with ischemic heart disease].	2004-12-21	15605830
[Moricizine in treatment of one case with tachycardia-induced cardiomyopathy].	2003-10	14731369
Moricizine induced increase in pacing threshold.	2003-01	12685150
Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A.	2002-12	12393941
Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block.	2002-03	12402511
Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation.	2001-01-15	11152834
[Mechanisms of action of hypersodium medium on contractile activity of isolated rat heart].	2001	11296555
Action of MgSO4 differs from moricizine and verapamil on ouabain-induced ventricular tachycardia in normomagnesemic conscious dogs.	1994-02	7511755
Effects of magnesium and ethmozin on ventricular tachycardia induced by ouabain and ventricular pacing in conscious dogs with complete atrioventricular block.	1993	8178656
Moricizine-induced proarrhythmia.	1992-11	10969633
The prevalence of proarrhythmic events during moricizine therapy and their relationship to ventricular function.	1992-10	1529903
Exercise induced fatal sinusoidal ventricular tachycardia secondary to moricizine.	1992-10	1383951
Proarrhythmia in patients treated with moricizine.	1992-09	1383982
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.	1992-07	1607582
Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias.	1992-03-01	1736771
Exacerbation of congestive heart failure secondary to moricizine.	1992	1437702
A cerebral computed tomography study of patients with drug-induced psychoses.	1991	1834188
Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.	1990-02-20	1689536
Congestive heart failure induced by six of the newer antiarrhythmic drugs.	1989-11-01	2509529
[Comparative study of the activity of anti-arrhythmia agents in calcium chloride-induced arrhythmia in mice].	1983-05-01	6861988
New drugs for treating cardiac arrhythmias.	1981-01	6780988

Patents

Sample Use Guides

In Vivo Use Guide

Patients with greater than or equal to 30 ventricular premature complexes (VPCs) per hour were given moricizine HCL (816 +/- 103 mg daily) as a three times oral daily dose. Moricizine suppressed 81% of VPCs alone and 87% of VPCs in combination with 120 mg of propranolol.

Route of Administration: Oral

In Vitro Use Guide

Single ventricular myocytes from guinea-pig hearts were prepared by enzymatic dissociation. Isolated single cells were transferred to a recording chamber of an inverted phase-contrast microscope which was maintained at 34 - 35 deg-C. Membrane currents were recorded by using whole-cell patch-clamp technique using an amplifier. Application of 1O micro-M moricizine was started at 7 minutes and continued up to 13 minutes after the formation of whole cell configuration. In the absence of drug, the current decayed with time and the average value of relative currents at 20 min was 0.48 ± 0.11. In the presence of 10 micro-M moricizine, the tail currents decreased progressively with time and the minimum value of 0.29 was reached at 13 min after rupture of the membrane (or 6 min after the application of moricizine).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:15:40 GMT 2025` Edited by `admin` on `Mon Mar 31 18:15:40 GMT 2025`
Record UNII	2GT1D0TMX1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MORICIZINE

Official Name

English

MORACIZINE

Preferred Name

English

EN-313 FREE BASE

Code

English

moracizine [INN]

Common Name

English

MORICIZINE [VANDF]

Common Name

English

Moracizine [WHO-DD]

Common Name

English

MORICIZINE [MI]

Common Name

English

MORACIZINE [MART.]

Common Name

English

Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate

Common Name

English

MORICIZINE [USAN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175426